CD44 has already been extensively described as a suitable antigen for tumor targeting since it is overexpressed in a plethora of cancers as lung (163, 164), prostate (165), colon (166, 167), ovarian (168) and others (169). The gene discussed is CD44; the disease is neoplasm.